BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30155861)

  • 21. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
    Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
    Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
    JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological validation of frequency domain optical coherence tomography for the evaluation of neointimal formation after a novel polymer-free sirolimus-eluting stent implantation.
    Fu Q; Hu H; Chen W; Tan Z; Li L; Wang D; Chen B
    Int J Clin Exp Pathol; 2015; 8(9):11068-75. PubMed ID: 26617825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
    Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
    Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
    Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
    JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel ultrahigh molecular weight amorphous PLLA bioresorbable coronary scaffold upsized up to 0.8 mm beyond nominal diameter: An OCT and histopathology study in porcine coronary artery model.
    Gasior P; Cheng Y; Estrada EA; Jenn McGregor ; Ramzipoor K; Lee C; Conditt GB; Rousselle SD; Granada JF; Kaluza GL
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):378-386. PubMed ID: 28471065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
    Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM
    EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strut protrusion and shape impact on endothelial shear stress: insights from pre-clinical study comparing Mirage and Absorb bioresorbable scaffolds.
    Tenekecioglu E; Sotomi Y; Torii R; Bourantas C; Miyazaki Y; Collet C; Crake T; Su S; Onuma Y; Serruys PW
    Int J Cardiovasc Imaging; 2017 Sep; 33(9):1313-1322. PubMed ID: 28365819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neointimal response to everolimus-eluting bioresorbable scaffolds implanted at bifurcating coronary segments: insights from optical coherence tomography.
    Sato T; Jose J; El-Mawardy M; Sulimov DS; Tölg R; Richardt G; Abdel-Wahab M
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):169-175. PubMed ID: 27757563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer-coated sirolimus-eluting stents.
    Legutko J; Gil RJ; Buszman PE; Kaluza GL; Mintz GS; Roleder T; Krol M; Wojdyla R; Pawlowski T; Brzezinski M; Kondys M; Skwarna B; Jakala J; Zasada W; Partyka L; Dudek D
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):302-309. PubMed ID: 29027737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent: The EGO-Combo Study.
    Lee SW; Lam SC; Tam FC; Chan KK; Shea CP; Kong SL; Wong AY; Yung A; Zhang LW; Tse HF; Wu KK; Chan R; Haude M; Mehran R; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27418609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
    Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
    Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
    EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
    Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
    JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold.
    Kochman J; Kołtowski Ł; Tomaniak M; Jąkała J; Proniewska K; Legutko J; Roleder T; Piertrasik A; Rdzanek A; Kochman W; Brugaletta S; Opolski G; Regar E
    EuroIntervention; 2018 Apr; 13(18):e2201-e2209. PubMed ID: 29155384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.
    Gil RJ; Bil J; Legutko J; Pawłowski T; Gil KE; Dudek D; Costa RA
    Int J Cardiovasc Imaging; 2018 Mar; 34(3):353-365. PubMed ID: 28965166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.